Clinical trials
Alzheimer’s disease clinical trials
A progressive brain disorder that affects memory and thinking. We’re tracking 601 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03019757Recruiting
Testing ways to tell dementia causes apart
This study looks at how to distinguish Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease when someone has memory and thinking problems. It may help doctors choose the most accurate diagnosis and treatment path for the right condition.
Columbus, OhioAges 18 years+ - NCT06869135Recruiting
Saliva testing for brain diseases
This trial is collecting saliva samples from people with Alzheimer's, Parkinson's, or other brain diseases to find new ways to diagnose them. It may help improve early detection.
Florence, FIAges 45 years+ - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85 - NCT07863011Recruiting
Low-dose brain radiation for mild Alzheimer's disease
This study tests a low dose of radiation to the whole brain combined with an experimental drug to see if it can slow down the effects of mild Alzheimer's disease. It aims to help people with mild dementia think more clearly and keep their daily abilities for as long as possible.
Cheonan, Chungcheongnam-doAges 60–85 - NCT07869238Recruiting
Safety study of NMS-01 for mild to moderate Alzheimer's disease
This trial tests a new treatment called NMS-01 for people with mild to moderate Alzheimer's disease. It aims to see if it's safe and may help with symptoms.
Seoul, SeodaemunAges 50–85 - NCT05176704Recruiting
Eye movement tests for Alzheimer's disease
This study looks at how people with Alzheimer's disease move their eyes compared to healthy people. The goal is to develop simple, non-invasive eye-tracking tests that could help diagnose Alzheimer's disease earlier and more accurately.
Montreal, QuebecAges 18 years+ - NCT07821658Recruiting
Lecanemab treatment study for Alzheimer's disease
This study looks at people who are taking or have taken lecanemab (a medication for Alzheimer's disease). It aims to gather more information about the treatment's effects in real-world settings.
Nutley, New JerseyAges Any age - NCT07758595RecruitingPhase 1
Study of DNL921 for healthy people and people with Alzheimer's disease
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
ManchesterAges 18–75 - NCT07764146RecruitingPhase 1
Study of VY1706 for early Alzheimer's disease
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
Maitland, FloridaAges 30–80 - NCT07717411RecruitingPhase 3
Trontinemab for people at risk of Alzheimer's symptoms
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Irvine, CaliforniaAges 55–80 - NCT07694921Enrolling by invitation
Non-invasive brain stimulation for Alzheimer's disease
This trial tests if a safe, non-invasive electrical stimulation can help people with Alzheimer's disease. It aims to improve thinking and memory skills.
Hangzhou, ZhejiangAges 60 years+ - NCT07672171Recruiting
Far-infrared therapy for Alzheimer's dementia
This study tests whether far-infrared therapy (a gentle heat treatment) can help people with Alzheimer's dementia. If you have mild-to-moderate Alzheimer's on medication, you may be able to join.
TaipeiAges 61–92 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Irvine, CaliforniaAges 50 years+ - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT07599670RecruitingPhase 1/Phase 2
Safety study of ABBV-1758 injection for Alzheimer's disease
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Irvine, CaliforniaAges 50–90 - NCT07570719Recruiting
Community screening for early Alzheimer's disease signs
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
Shanghai, Shanghai MunicipalityAges 60–80 - NCT07496021Recruiting
Probiotic for early Alzheimer's: safety and memory benefits
This trial tests a new probiotic (Lactococcus lactis CKDB001) to see if it can slow memory loss in people with early Alzheimer's. It’s a 12-week study that requires a positive amyloid PET scan and allows mild to moderate symptoms.
Gyeonggi-doAges 55–85 - NCT04312399Recruiting
Hormone treatment study for Alzheimer risk in postmenopausal women
This study looks at whether hormone treatment can help prevent or slow Alzheimer’s disease in women who have gone through menopause. It may help by testing a hormone-based approach in a carefully selected group.
GhentAges 40–65 - NCT06833645Recruiting
PET scans to spot early Alzheimer's changes
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
Chengdu, SichuanAges 18 years+ - NCT07341009Recruiting
Study of time processing skills in Alzheimer's disease
This study uses a brain game to measure how people with Alzheimer's disease process the passage of time. The goal is to better understand this ability, which could lead to new ways to support patients.
CaenAges Any age - NCT07324161Recruiting
Magnetic Brain Stimulation for Alzheimer's Disease
This trial tests whether a non-invasive magnetic brain stimulation treatment (TMS) can help people with mild to moderate Alzheimer's disease. You would receive the treatment and be monitored for safety and benefit.
Fuzhou, FujianAges 50–90 - NCT07214727RecruitingPhase 1
A study of ALN-5288 for Alzheimer's disease
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
MontrealAges 40–80 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Maitland, FloridaAges 50–85
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer’s disease?
- Yes. Clin2 currently lists 601 recruiting alzheimer’s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer’s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.